Latest Articles
Endometrial cancer, Bellet (Acto): "Ensure access to new therapies nationwide." - lamilano.it
Endometrial cancer, Bellet (Acto): "Ensure access to new therapies nationwide." lamilano.it
Published: Feb. 23, 2026, 5:18 p.m.
Endometrial cancer, Campagnoli (GSK): "Immunotherapy increases overall survival." - lamilano.it
Endometrial cancer, Campagnoli (GSK): "Immunotherapy increases overall survival." lamilano.it
Published: Feb. 23, 2026, 5:15 p.m.
Weekly review: Endometriosis updates, ISSWSH coverage, and more - Contemporary OB/GYN
Weekly review: Endometriosis updates, ISSWSH coverage, and more Contemporary OB/GYN
Published: Feb. 23, 2026, 5:12 p.m.
Endometrial cancer, Lorusso (Humanitas): "Immunotherapy is effective even in pMMR forms." - lamilano.it
Endometrial cancer, Lorusso (Humanitas): "Immunotherapy is effective even in pMMR forms." lamilano.it
Published: Feb. 23, 2026, 5:12 p.m.
Adjustable Continence Therapy data for SUI, with Sasha Vereecken - Contemporary OB/GYN
Adjustable Continence Therapy data for SUI, with Sasha Vereecken Contemporary OB/GYN
Published: Feb. 23, 2026, 3:52 p.m.
Absci's 2026 Roadmap: Clinical Catalysts and Strategic Communication - AD HOC NEWS
Absci's 2026 Roadmap: Clinical Catalysts and Strategic Communication AD HOC NEWS
Published: Feb. 23, 2026, 3:51 p.m.
‘I am hopeful’: Springbok WAG Holly le Roux inspires as she shares her infertility journey - News24
‘I am hopeful’: Springbok WAG Holly le Roux inspires as she shares her infertility journey News24
Published: Feb. 23, 2026, 3:05 p.m.
PCOS Long-Term Health Risks: From Infertility And Type 2 Diabetes To Heart Disease And Endometrial Cancer - TheHealthSite
PCOS Long-Term Health Risks: From Infertility And Type 2 Diabetes To Heart Disease And Endometrial Cancer TheHealthSite
Published: Feb. 23, 2026, 1:56 p.m.
Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. - lamilano.it
Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. lamilano.it
Published: Feb. 23, 2026, 1:30 p.m.
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress - The Manila Times
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress The Manila Times
Published: Feb. 23, 2026, 1:16 p.m.
Link copied to clipboard!